

"Low FODMAP means avoiding all high-FODMAP food forever"

- Low FODMAP is second line treatment for IBS
- Around 60% efficacy for symptom relief
- 3 phases
- Goal is to expand the diet as much as possible, and **avoid unnecessary restrictions**
- **Dietician involvement** have higher success rates and better nutritional outcomes



Eswaran et al – Am J Gastro 2016 O'Keeffee et al – Journal of Gastroenterology and Hepatology 2018



Why a **dietician?**

- Low FODMAP diet is challenging
 - Monitoring is required to avoid nutritional deficiencies and overly restrictive eating habits
- Avoidant/Restrictive Food Intake Disorder (ARFID)
 - Not an eating disorder
 - Maladaptive generalized overrestriction of food from fear of aversive consequences (e.g. exacerbating DGBI symptoms)
 - Around 25% of DGBI presentations
 - 3x risk with prior exclusion diets
 - NIAS screening tool

Summary

Myths Debunked

- X "IBS is all in the head": DGBI involves gut-brain axis dysfunction.
- X "Leaky gut/SIBO causes IBS": No proven causal link; SIBO is a comorbidity, not root cause.
- 🔀 "Food allergy tests diagnose IBS": IgG, hair analysis lack validity and doesn't guide therapy
- X "Gluten-free diets cure IBS": Often FODMAP intolerance; gluten free not always better

Clinical Takeaways

II Epidemiology: 1/3 of IBS sufferers are male; significant burden

Nanagement:

Second-line therapies: Rifaximin (IBS-D), TCAs (pain), peppermint oil (bloating). Probiotics: NNT 7, but strains unclear; not universally recommended. *FMT*: Inconsistent efficacy; reserve for research.

🥙 Diet:

Prioritize **soluble fiber** (oats, chia); reduce insoluble fiber. **Low FODMAP**: 60% efficacy; Dietitian-led to avoid nutritional complications.

Guidelines

ACG/BSG: Avoid non-validated tests (SIBO breath tests); focus on evidence-based therapies.

Thank you

Any questions? Get in touch!

Henry@glms.co.nz

Dr Henry Wei https://www.gastroconsult.net/

Guidelines IBS

American college of Gastroenterology 2021

American Gastroenterology Association 2022

British Society of Gastroenterology 2022

G Clinical Guideline: Management of wel Syndrome

E. Lacy, PhD, MD, FACG¹, Mark Pimentel, MD, FACG², Darren M. Brenner, MD, FACG³, A. Keefer, PhD⁵, Millie D. Long, MDMPH, FACG (GRADE Methodologist)⁶ and Baha Mo:

Gastroenterology 202

GUIDELINES

AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation

Lin Chang,^{1,*}Shahnaz Sultan,^{2,3,*}Anthony Lembo,⁴ G. Nicholas Verne,⁵ Walter Sma Joel J. Heidelbaugh⁷

tish Society of Gastroenterology guide anagement of irritable bowel syndrom

sch H.Vacant n 1,2 Potor A Daine 3 Christopher I Black n 4